Belite Bio (BLTE) Cash & Current Investments (2021 - 2025)

Belite Bio has reported Cash & Current Investments for 5 years, with the latest figure at $476.8 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Current Investments rose 239.1% year-over-year to $476.8 million; the trailing twelve-month figure through Dec 2025 stood at $476.8 million (up 239.1% YoY), and the FY2025 full-year result was $476.8 million, up 239.1% from the prior year.
• Cash & Current Investments for Q4 2025 stood at $476.8 million, up from $140.6 million in the prior quarter.
• The five-year high for Cash & Current Investments was $476.8 million in Q4 2025, with the low at $17.3 million in Q4 2021.
• Average Cash & Current Investments over 5 years is $153.0 million, with a median of $88.2 million recorded in 2023.
• Year-over-year, Cash & Current Investments soared 59.49% in 2024 and soared 239.1% in 2025.
• Tracing BLTE's Cash & Current Investments over 5 years: stood at $17.3 million in 2021, then soared by 142.67% to $42.1 million in 2022, then surged by 109.45% to $88.2 million in 2023, then soared by 59.49% to $140.6 million in 2024, then soared by 239.1% to $476.8 million in 2025.
• The last three Cash & Current Investments figures came in at $476.8 million (Q4 2025), $140.6 million (Q4 2024), and $88.2 million (Q4 2023), per Business Quant data.

Peer Comparison